TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26370118

Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 47
Study: 24827384

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 300mg tablets, two times per day for six months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (Control Group B)
Number of subjects: 32
Study: 23475541

Group type: EXPERIMENTAL
Intervention: Lamotrigine XR
Number of subjects: 662

Group type: COMPARATOR
Intervention: Lamotrigine IR
Number of subjects: 662
Study: 20538235

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg tramadol (Group T)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.75 mg/kg tramadol plus 1 g of paracetamol (Group P)
Number of subjects: 60
Study: 18165641

Group type: EXPERIMENTAL
Intervention: PCB (Bevacizumab in combination with carboplatin and paclitaxel)
Number of subjects: 224

Group type: COMPARATOR
Intervention: PC (Carboplatin and paclitaxel)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: PCB
Number of subjects: 224

Group type: COMPARATOR
Intervention: PC
Number of subjects: 224
Study: 15906418

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (Blosart, Julphar, UAE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Losartan 50 mg (Cozaar, MSD, The Netherlands)
Number of subjects: 24
Study: 12905137

Group type: EXPERIMENTAL
Intervention: Asymptomatic infection with Borrelia burgdorferi
Number of subjects: 0
Study: 10509575

Group type: EXPERIMENTAL
Intervention: MOS-HIV
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: MQOL-HIV
Number of subjects: 558

Group type: COMPARATOR
Intervention: Healthy blood donors
Number of subjects: 558
Study: 8941830

Group type: EXPERIMENTAL
Intervention: Ketac‐Fil, finished immediately
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketac‐Fil, finished after a delay
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chelon‐Fil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cervident (resin composite)
Number of subjects: 30
Study: 1744385

Group type: EXPERIMENTAL
Intervention: 0.1 N HCl infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 19
Study: 7027708

Group type: EXPERIMENTAL
Intervention: Progestogen only (Lynestrenol 0.5 mg daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (Ethinyl oestradiol 50 μg + lynestrenol 2.5 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-hormonal intrauterine device (IUD)
Number of subjects: 38
Study: 31764994

Group type: EXPERIMENTAL
Intervention: Fruit diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Invertebrate diet
Number of subjects: 40
Study: 31053668

Group type: EXPERIMENTAL
Intervention: Neuromuscular ultrasound (NMUS) added to electrodiagnostic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrodiagnostic testing alone
Number of subjects: 0
Study: 28950844

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 2 weeks before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 40
Study: 27422275

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) programme, one session every 2 weeks for 10 weeks, with telephone contact every 2 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention, one session every 2 weeks for 10 weeks, with telephone contact every 2 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Active waiting-list control group provided claims processing-related reading material, with telephone contact every 2 weeks for 10 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) programme
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Active waiting-list control group
Number of subjects: 180
Study: 24142751

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI) in patients with CRD
Number of subjects: 103
Study: 22328727

Group type: EXPERIMENTAL
Intervention: 1% CLA supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: LPS challenge
Number of subjects: 32
Study: 19237734

Group type: EXPERIMENTAL
Intervention: T‐WREX
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tabletop exercise
Number of subjects: 28
Study: 17557981

Group type: EXPERIMENTAL
Intervention: Computed tomography scans at multiple intervertebral positions (L2-L3, L3-L4, L4-L5)
Number of subjects: 24
Study: 15333719

Group type: EXPERIMENTAL
Intervention: Strong-gelling alginate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no added gelling agent)
Number of subjects: 12
Study: 12587625

Group type: EXPERIMENTAL
Intervention: Single dose of ornidazole 30 mg/kg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Single dose of ornidazole 25 mg/kg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Single dose of ornidazole 20 mg/kg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ornidazole 25 mg/kg per day for 5 days
Number of subjects: 175

Group type: COMPARATOR
Intervention: Metronidazole 20 mg/kg per day for 7 days
Number of subjects: 175
Study: 9691361

Group type: EXPERIMENTAL
Intervention: Intravenous anti-D (200 micrograms)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intramuscular anti-D (200 micrograms)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both intravenous and intramuscular anti-D
Number of subjects: 11
Study: 7857498

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 2527132

Group type: EXPERIMENTAL
Intervention: 60 g day‐1 of crystalline fructose in divided amounts as part of their isocaloric diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual diabetic diet (control)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 60 g day‐1 of crystalline fructose
Number of subjects: 13
Study: 402088

Group type: COMPARATOR
Intervention: 600 gm/24 hours glucose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 gm/24 hours combination of glucose, fructose, and xylitol
Number of subjects: 12
Study: 31649219

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2.4 ATA for 90 minutes in addition to conventional wound care
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional wound care only
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 58
Study: 29281988

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (AS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intravenous quinine (QNN)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Molecular genotyping
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ACT administered
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 300
Study: 26005259

Group type: EXPERIMENTAL
Intervention: Oral diclofenac + oral B vitamin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Oral diclofenac + oral vitamin E
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral diclofenac + placebo
Number of subjects: 108
Study: 23503879

Group type: EXPERIMENTAL
Intervention: PCNL after failed SWL (group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: PCNL as first treatment (group 2)
Number of subjects: 62
Study: 21816019

Group type: EXPERIMENTAL
Intervention: Osteoporosis Prevention and Self‐Management Course (OPSMC) (4 × 2.5 h)
Number of subjects: 146

Group type: COMPARATOR
Intervention: One-session course (1 × 2.5 h)
Number of subjects: 146
Study: 19451765

Group type: EXPERIMENTAL
Intervention: 1.8 g/d omega-3
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (R.P. Scherer)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 17049642

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3532

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 3532

Group type: COMPARATOR
Intervention: Combined endpoint (CABG vs PCI)
Number of subjects: 3532

Group type: COMPARATOR
Intervention: Combined endpoint (adjusted)
Number of subjects: 3532

Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 3532
Study: 15138617

Group type: EXPERIMENTAL
Intervention: 600 ml coffee/day and a supplement of 200 microg folic acid/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12691171

Group type: EXPERIMENTAL
Intervention: Mediterranean or low-fat diets
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard Western diet
Number of subjects: 300
Study: 9650545

Group type: EXPERIMENTAL
Intervention: Intravenous terazosin (7.5 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral terazosin (1 mg on day 1, 2 mg on day 2, and 5 mg on days 3 and 4)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous terazosin (2.5 mg, 5 mg, or 7.5 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous terazosin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral terazosin
Number of subjects: 31
Study: 8031158

Group type: EXPERIMENTAL
Intervention: UFT group (300 mg/day for one year)
Number of subjects: 560

Group type: COMPARATOR
Intervention: non-treatment group
Number of subjects: 560
Study: 2688079

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam once-daily
Number of subjects: 307

Group type: COMPARATOR
Intervention: 100 mg ketoprofen b.i.d.
Number of subjects: 307
Study: 31968595

Group type: EXPERIMENTAL
Intervention: Preoperative whey protein-infused carbohydrate loading and postoperative early oral feeding (CHO-P)
Number of subjects: 118
Study: 28103110

Group type: EXPERIMENTAL
Intervention: Fathers Supporting Success in Preschoolers: A Community Parent Education Program (Dialogic Reading)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 126
Study: 27765310

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound using the CardioProlific Genesis System followed by local administration of a liquid mixture of iopromide 370 and paclitaxel 1.0 μg/mm3
Number of subjects: 56

Group type: COMPARATOR
Intervention: Drug-eluting balloons
Number of subjects: 56
Study: 27858749

Group type: EXPERIMENTAL
Intervention: Exercise intervention (individualized home-based cycling and strengthening) for 6 months, followed by both groups receiving the intervention for an additional 12 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 14
Study: 22486580

Group type: EXPERIMENTAL
Intervention: Antidepressant monotherapy (ADM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination antidepressant therapy (CAD)
Number of subjects: 60
Study: 20190720

Group type: EXPERIMENTAL
Intervention: C/T-13910 single nucleotide polymorphism genotyping assay
Number of subjects: 123

Group type: COMPARATOR
Intervention: Comparison with existing data from other Italian regions
Number of subjects: 123
Study: 19122339

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 47
Study: 15924540

Group type: EXPERIMENTAL
Intervention: Pubovaginal sling
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transurethral Macroplastique
Number of subjects: 45
Study: 12931378

Group type: EXPERIMENTAL
Intervention: Feilinjian peroral liquid
Number of subjects: 203

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 203
Study: 10321528

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin 0.2 mg/ml for 5 minutes
Number of subjects: 36

Group type: COMPARATOR
Intervention: Postoperative mitomycin 0.2 mg/ml four times a day for 7 days
Number of subjects: 36
Study: 8917000

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 micrograms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mifepristone 200 mg
Number of subjects: 100
Study: 1886479

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution at 26 g.h(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution at 52 g.h(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution at 78 g.h(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate feeding
Number of subjects: 10
Study: 6814928

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion at 3.4 micrograms/min
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion at 7.5 micrograms/min
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30921502

Group type: EXPERIMENTAL
Intervention: Twice-weekly 28.2-μg teriparatide injections
Number of subjects: 100

Group type: COMPARATOR
Intervention: Once-weekly 56.5-μg teriparatide injections
Number of subjects: 100
Study: 30851316

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) during motor tasks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) during tri session paradigm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 28645287

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1717
Study: 25899989

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24353120

Group type: EXPERIMENTAL
Intervention: Ablation with argon plasma coagulation (APC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 63
Study: 23211896

Group type: EXPERIMENTAL
Intervention: Diluted formocresol (DFC)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Gray mineral trioxide aggregate (GMTA)
Number of subjects: 168
Study: 18774751

Group type: EXPERIMENTAL
Intervention: ProDisc-C
Number of subjects: 209

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 209
Study: 17912165

Group type: EXPERIMENTAL
Intervention: Emergency Percutaneous Coronary Intervention (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (especially abciximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel with aspirin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bare-metal stents (BMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-coronary (IC) injection of drugs
Number of subjects: 0
Study: 16274414

Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization Therapy with Defibrillator)
Number of subjects: 0
Study: 12144585

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.d.s. (n=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.d.s.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cisapride 10 mg t.d.s. and Placebo
Number of subjects: 19
Study: 10556006

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 35
Study: 10150860

Group type: EXPERIMENTAL
Intervention: Therapeutic options that attempt to moderate intraocular pressure (IOP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic options that attempt to alter blood flow
Number of subjects: 0
Study: 1976937

Group type: EXPERIMENTAL
Intervention: Specialist clinic treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: General practitioner (GP) treatment
Number of subjects: 40
Study: 7468115

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine 0.75%
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia with thiopentone, fentanyl, pancuronium, N2O/O2
Number of subjects: 60
Study: 30915972

Group type: EXPERIMENTAL
Intervention: Peer-play activities
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 29912061

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg oral)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 27651843

Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Treatment (OMT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 14
Study: 24561029

Group type: EXPERIMENTAL
Intervention: Protocolized measurement of MEWS three times daily
Number of subjects: 3585

Group type: COMPARATOR
Intervention: Control group measuring MEWS when clinically indicated
Number of subjects: 3585
Study: 22308559

Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Neurodevelopmental Treatment (NDT/Bobath)
Number of subjects: 28
Study: 21048211

Group type: EXPERIMENTAL
Intervention: 1200 mg of oral aloe vera powder
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study: 17194824

Group type: EXPERIMENTAL
Intervention: Intravenous flucytosine at 100 mg/kg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral flucytosine at 100 mg/kg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous flucytosine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral flucytosine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both formulations (oral and intravenous)
Number of subjects: 32
Study: 15256418

Group type: COMPARATOR
Intervention: Twins after assisted conception
Number of subjects: 3393

Group type: EXPERIMENTAL
Intervention: Children conceived by ICSI
Number of subjects: 3393
Study: 11603960

Group type: EXPERIMENTAL
Intervention: Olestra-containing potato chips
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular fat-containing potato chips (placebo)
Number of subjects: 14
Study: 9440412

Group type: EXPERIMENTAL
Intervention: Strengthening exercises in their homes three times a week for 10 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal activities
Number of subjects: 100
Study: 8015127

Group type: EXPERIMENTAL
Intervention: Blinded reviewers
Number of subjects: 4

Group type: COMPARATOR
Intervention: Nonblinded reviewers
Number of subjects: 4

Group type: COMPARATOR
Intervention: Editors
Number of subjects: 4
Study: 2492414

Group type: EXPERIMENTAL
Intervention: Interrupted Smead‐Jones far‐far‐near‐near sutures
Number of subjects: 2

Group type: COMPARATOR
Intervention: Running sutures
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Running #1 polydioxanone (PDS) suture
Number of subjects: 2

Group type: COMPARATOR
Intervention: #1 polypropylene (Prolene) suture
Number of subjects: 2
Study: 1102614

Group type: EXPERIMENTAL
Intervention: Alice strain vaccine intranasally
Number of subjects: 199

Group type: COMPARATOR
Intervention: Bivalent inactivated influenza vaccine intramuscularly
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo intranasally
Number of subjects: 199
Study: 31044450

Group type: EXPERIMENTAL
Intervention: HVI injection with corticosteroid
Number of subjects: 28

Group type: COMPARATOR
Intervention: HVI injection without corticosteroid
Number of subjects: 28
Study: 25416688

Group type: EXPERIMENTAL
Intervention: Rank preserving structural failure time models (RPSFTM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iterative parameter estimation methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverse probability of censoring weights method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structural nested models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simplified two-stage Weibull method
Number of subjects: 0
Study: 26225498

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation with PEEP (positive inspiratory pressure: 12 cmH2O, PEEP: 6 cmH2O)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation without PEEP (positive inspiratory pressure: 12 cmH2O)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 0
Study: 21964284

Group type: EXPERIMENTAL
Intervention: Pavlovian safety signal training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instrumental avoidance response training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported shock expectancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin conductance responses
Number of subjects: 0
Study: 22168568

Group type: EXPERIMENTAL
Intervention: 200 mg Aspirin for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 3 years
Number of subjects: 0
Study: 19169631

Group type: EXPERIMENTAL
Intervention: DrotAA (recombinant activated protein C)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 16863391

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 13
Study: 14616153

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (erosive oesophagitis)
Number of subjects: 26
Study: 16825934

Group type: EXPERIMENTAL
Intervention: 4-day rabeprazole, levofloxacin, tinidazole (RLT)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole, levofloxacin, tinidazole (RLT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 169
Study: 10580457

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice per day
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice per day
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice per day
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice per day
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1149
Study: 8967597

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No heat and moisture exchanger (Control)
Number of subjects: 22
Study: 1848966

Group type: EXPERIMENTAL
Intervention: Local anesthetic sympathetic ganglion blocks (LASB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phentolamine blocks (PhB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both LASB and PhB
Number of subjects: 20